Precision medicine for
all of humanity.
Xeomics delivers national genomic programs and precision medicine infrastructure for the populations global medicine has overlooked.
Modern medicine was built almost entirely on US and European data. Most of humanity was left out of the research that defines their care.
That gap is a scientific and moral failure. Xeomics exists to correct it by turning underrepresented populations from an afterthought into the foundation of better, more equitable medicine for everyone.
60%+ sourced outside the US & Europe
+ 1M+ physicians worldwide
One platform, four reinforcing businesses
Each business is valuable on its own. Together they form a single loop in which data improves care and care generates more data. Explore each.
Multimodal Data
Diverse real-world dataGenomics
Programs & reportingSeraya Health
Connected chronic careNexa
Engagement networkDiverse, multimodal data at population scale
We partner directly with hospital networks in markets the data industry has overlooked, then de-identify, structure and enrich their records into a research-grade asset — each patient's full episodic journey across records, imaging, labs and genomics.
- 500M+ longitudinal patient records
- De-identified at source, retained in perpetuity
- Licensed to pharma, CROs and AI companies
Built for everyone who shapes global health
Governments
Stand up a sovereign, world-class national genomic program.
Pharma & CROs
Diverse RWD/RWE and cohorts you can't get anywhere else.
Biotech
Population-scale genomics and cohorts to power discovery.
AI & Technology
Consented, ethically-sourced, ethnically-diverse training data.
Providers & Labs
World-class genomic & PGx reporting under your own brand.
Diverse real-world evidence, market-access and reimbursement studies, and bespoke disease cohorts built from data you can't source elsewhere.
Reach the non-US trial populations 63% of recruiting studies now need1 — and structure trials in a fraction of the usual time.
Consented, ethically-sourced, ethnically-diverse training data — plus synthetic data for adjacent industries.
Commercializing data assets, building AI models, and embedding genomics into prescribing systems with M42 and Abu Dhabi Health Data Services.
An outsourced commercial engine shaping data-licensing deals with several leading AI companies.
White-label longevity and women's-health solutions that channel customers into Seraya — from wellness into managed care.
A partnership anchoring Xeomics' cardiovascular work in recognized clinical leadership.
Diverse, consented, global data
We capture each patient's full episodic journey — records, imaging, labs and genomics — de-identified under local law and onboarded into a government-grade secure cloud. Modern AI models can't source this diversity elsewhere, making it one of the only consented, ethnically-diverse training-data assets available to license.
Globally & ethnically diverse
Longitudinal data from the non-US/non-European populations historically excluded from medical research.
Exclusive & enduring
Hospital partnerships are exclusive for 5+ years; de-identified data is retained in perpetuity. A growing, defensible asset.
Consent & compliance first
Patient consent, de-identification and linkage permissions aligned to GDPR and local jurisdictional law.
Government-grade security
De-identified, replicated and secured in Syntium Cloud, our proprietary government-grade data platform.
Faster than procurement
Because data is pre-consented and onboarded into Syntium Cloud, partners skip months of procurement — value delivered in days to weeks, not months.
Enriched for research
Cleansed, coded, translated, linked and enriched with genetic and behavioral context — research-ready.
Sovereign genomic programs, built to last
We don't just sequence; we build national capability that reduces costs and improves health outcomes. Cohort design, a genomic centre of excellence, local capacity building, and data governance and security implemented to be retained and sustained by the nation.
Design disease-relevant national cohorts
We help governments and health systems build genomic programs around the diseases and populations that matter most locally — not just healthy volunteer datasets. This creates more useful data for clinical care, public health, and research.
Deploy sequencing, reporting, and clinical infrastructure
Xeomics supports end-to-end program execution, from cohort design and sequencing workflows to precision medicine and pharmacogenomic reporting. The result is a practical national capability that can be embedded into routine care.
Link genomics with real-world clinical data
National programs become more powerful when genomic data is connected to longitudinal health records, outcomes, and population-level disease patterns. This enables earlier risk detection, more personalized treatment, and better public-health planning.
Create a platform for discovery and long-term value
By combining population-scale genomics with clinical context, national programs can support biomarker discovery, drug-target identification, and AI-driven research. Countries retain sovereign control of their primary data while participating in the value created from future discoveries.
World-class genomic reporting, white-labelled for you
A turnkey genomic and pharmacogenomic reporting solution for governments, hospitals, labs, clinics and life-sciences institutions — patient-friendly summaries backed by clinician-grade detail and full scientific bibliography.
Our Tier-1 pharmacogenomic report is among the most comprehensive available — 500+ drugs, 1,060 genes, 2,725 markers — generated from both whole-genome and exome-based sequences.
- Metabolic
- Oncology
- Cardiovascular
- Colorectal cancer
- Prostate cancer
- Wellbeing
- Pharmacogenomic
36 clinical reports span blood & immune, cardiovascular, sensory, endocrine, gastrointestinal, mental health, skin, bone & muscle, nephrological, neuronal, reproductive and respiratory disease groups.
Illustrative sample for demonstration only — not a real patient result.
Where the data loop drives better patient outcomes
Seraya combines health records, genomic insight, and real-time wearables data, then applies AI-driven coaching to deliver personalized care pathways for chronic conditions.
Genomic insight
A genomic profile personalizes each patient's care pathway from the start.
Continuous monitoring
Real-time signals from wearable devices keep care responsive between visits.
AI coaching
Adaptive guidance that responds to the patient's own data, day to day.
Recurring & sticky
A subscription model with strong retention as patients see daily, measurable benefit.
Continuous glucose monitoring plus data-driven care. Early results show reduced insulin dependence under physician supervision and signs of improved glucose regulation.
Insight from records, genetics and wearables combined into one continuous view.
The same integrated, data-driven model applied to neurological conditions.
Reaching the right people, at speed and scale
Nexa is the connective tissue of the platform — a global, on-demand network linking life sciences directly to verified clinicians and patients for trials, surveys, advisory boards and messaging.
Verified participants
Clinicians and patients, screened across specialties, geographies and health systems.
Rapid execution
Studies fielded fast, with rigorous screening and compliance.
Integrated perspectives
Patient outcomes linked to HCP insight in one place.
Short, targeted surveys executed rapidly across specialties and geographies.
Structured expert engagement to shape strategy and consensus.
Faster enrollment for trials and longitudinal engagement programs.
Standing data collection embedded directly into clinical workflows.
Ongoing programs that keep patients connected and contributing data.
Insight for consultancies and medical-communications agencies.
1B+ patients and 1M+ clinicians reachable worldwide for targeted, criteria-based engagement.
The future of health is data-driven — and it's being built unequally
Projected annual revenue from healthcare data and platforms by 2040 (Deloitte, Future of Health).
Projected CAGR of the AI-in-healthcare market through 2029 (MarketsandMarkets).
Of clinical trials now recruiting patients enroll exclusively outside the United States1 — where diverse data is scarce.1. ClinicalTrials.gov — Trends, Charts & Maps (NLM; accessed Jun 2026).
An accomplished, cross-disciplinary team for a sovereign-scale mission
Healthcare, data, AI, cybersecurity, finance and global affairs — built to operate with governments and the world's largest institutions.
Former head of AI & Data, Publicis Sapient. Built and sold a business to Publicis.
Investment banker; ex-JPMorgan, BofA, UBS. Structured investments, fintech and asset management.
Serial technology entrepreneur; strategy and BD leader across Asia and the Middle East.
Former First Sea Lord, head of the UK Royal Navy (2013–16); cybersecurity authority.
Data-trust pioneer; ex-Accenture and Willis Towers Watson; PhD in AI for medicine.
Former VP Global Product Development, Clarivate; founder & CEO of Patient Connect.
Former Global Lead of Secondary Data, OPEN Health; 20 years in real-world data.
Technology & solutions leader; ex-Goldman Sachs, Deutsche Bank and AT&T Bell Labs.
Former Managing Director, Genomics England; leader at Cancer Research UK.
Former Chief Data Officer, Capgemini & Dentsu.
Former Creative Director, Publicis Sapient.
Former Delivery Lead for Publicis Groupe flagship AI program.
The latest from Xeomics
Company news and perspectives on genomics, precision medicine, AI and global health equity.
Xeomics joins the Global Alliance for Genomics & Health (GA4GH)
Now an Organizational Member of GA4GH — a milestone in our mission to advance responsible genomics and global health-data innovation.
Read article →Gene therapies: why lowering costs depends on AI and data diversity
By Dr George Zarkadakis. Gene therapies have moved from science fiction to clinical reality — yet the cost remains staggering.
Read article →Amplifier Health partners with Xeomics to scale voice biomarker technology
A strategic partnership to advance healthcare diagnostics through pioneering voice-based acoustic models.
Read article →Unlocking personalized medicine through pharmacogenomics
Imagine a world where your doctor prescribes medication tailored specifically to your DNA. That is the promise of pharmacogenomics.
Read article →Diverse global clinical datasets are critical for the future of drug research
Drug discovery too often relies on data drawn from predominantly white populations — limiting how well conclusions generalize to the majority of humanity.
Read article →Build the future of equitable medicine with us
Whether you're a government, a life-sciences partner, a data or AI team, a provider, or an investor, start the conversation.